title: FDA. Once on 'fast track,' avastin now derailed.
authors: Jennifer
authors: J
authors: Couzin-Frankel
authors: Yasmin
authors: Y
authors: Ogale
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D017277:Drug Approval; D016527:Drug Costs; D005260:Female; D006801:Humans; D015996:Survival Rate; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab